key: cord-0945114-jet2q377
authors: Roy Chattopadhyay, Nabanita; Chatterjee, Koustav; Banerjee, Antara; Choudhuri, Tathagata
title: Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters
date: 2020-11-11
journal: Virusdisease
DOI: 10.1007/s13337-020-00631-w
sha: ba0a04ae6dd771f9735ecf38893e3f9db4047a50
doc_id: 945114
cord_uid: jet2q377

SARS-CoV-2, or novel coronavirus, is causing the fatal and contagious coronavirus disease-2019 (COVID-19) affecting thousands of people every single day. Researchers are continuously searching for any possible cure and/or vaccine, but no conclusive report is available till date. Like many others, we realize that a rapid, immediate, and elaborate strategy must be adopted to protect mankind. To avoid the time-loss due to clinical trials, we have performed in silico analyses on some FDA-approved drugs to combat COVID-19. We accessed information from public databases and publications, and studied the mechanism of infection of SARS-CoV-2 and the interactions of various drugs with SARS-CoV-2 proteins in silico. We found a few antivirals and antiparasitic drugs to show significant interactions with important SARS-CoV-2 proteins. Particularly Galidesivir, Remdesivir, and Pirodavir have been chosen as suggested antiviral drugs; and Proguanil, Mefloquine, and Artesunate have been chosen as suggested antiparasitic drugs based on such predicted interactions. In addition, inhibitors to prevent host-cell entry and a few supportive immune-boosters can be used in different combinations. Our study proposes a four-way attack to this fatal virus for the possible management of COVID-19 armed up with an antiviral, an antiparasitic drug, a cell-entry inhibitor, and a few supportive immune-boosters, which can be used in different combinations in different groups of people. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13337-020-00631-w) contains supplementary material, which is available to authorized users.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or novel coronavirus, is the causative agent of the fatal and contagious coronavirus disease-2019 (COVID- 19) , which has first been reported in December, 2019 in the capital of Hubei province in China, named Wuhan [4, 26] . Since then, it has continued to spread throughout the world irrespective of the socio-economic status, ethno-genetic diversity, and topographical differences [3, 40] . According to World Health Organization (WHO), the disease is a Public Health Emergency of International Concern (PHEIC) and symptoms include dry cough, fever, breathing trouble, and other symptoms of common flu; however, death due to severe pneumonia and multi-organ failure is noted in immune-compromised people [3, 40] . The situation is frightening as the basic reproduction number (R 0 ) of the virus is 1. 4-3.9 in different countries, i.e. one infected person can infect 1.4-3.9 new people [1, 3, 40] . Considering the huge population of human beings and the universal susceptibility towards this virus, this can pose a serious threat to mankind. Unfortunately, no cure or vaccine is known till date. And finally, the most alarming one is, the mechanism of infection of this virus is quite complex and it might be present in other mammals also [1, 33, 36, 40, 41, 44, 45] . The infection usually spreads during close contact with infected persons through respiratory droplets produced by coughing and sneezing [29, 40] . Diagnosis can be done by antigen or antibody test in the suspected person and be confirmed by reverse transcription polymerase chain reaction (rRT-PCR) taking a nasopharyngeal swab [3, 22] . Incubation period of the virus may be as long as 2 weeks or even more; therefore social distancing, use of masks, hand washing, personal hygiene, and healthy lifestyle are the only methods suggested to prevent the infection [3, 40] .

SARS-CoV-2 is a positive-sense single-stranded RNA virus (?ssRNA virus) which uses its RNA as its genetic material as well as mRNA for the viral protein production (Fig. 1a-c) [22, 29, 40] . The individuum belongs to the realm Riboviria, order Nidovirales, family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus, and species Severe acute respiratory syndrome related coronavirus [17] . Though this virus shows significant homology with the bat-coronaviruses and its homologue found in pangolins, the severity and mode of infection of SARS-CoV-2 is attributed to the presence of a cleavage site for furin endoproteases in the junction of the S1 and S2 domains of the spike glycoprotein [20, 22, 33, 44, 45] . The S1 part attaches the virion to host-ACE2 (angiotensin-converting enzyme 2), a cell-surface receptor found in various tissue types including the alveolar epithelial cells, and is internalized inside the endosome. This primes the S2 by cleaving the S1/S2 junction by the cellular serine protease, transmembrane protease serine 2 (TMPRSS2), which actually is a furin endoprotease, and unmasks it for the fusion of the viral and cellular endosome membranes. This fusion facilitates the viral genome to enter into the cytoplasm of the host cell and establish infection [8, 9, 17, 20, 33] .

Immediately after entering, the viral RNA uses the hostcell's protein synthesis machinery for producing its own proteins. The details of the nucleotide sequences, their respective peptide sequences, structures, and the annotated functions are available in public database (https://swiss model.expasy.org/repository/species/2697049) [3, 17, 29] . Two-thirds of the genome, called the ORF1ab is responsible for producing the ORF1ab replicase polyprotein; this actually produces a set of 16 mature viral proteins (each called a non-structural protein or nsp) needed for different aspects of establishment of infection [3, 8, 9, 17, 20, 40] . The remaining parts encode the spike glycoprotein (S), small envelope protein (E), matrix protein (M), nucleocapsid protein (NC), and some accessory proteins to evade the host immune system. nsp1, the first protein synthesized just after the 5 0 UTR of the viral mRNA, binds the host 40S ribosomal subunit and stops host protein production by cleaving host-mRNAs near their 5 0 UTRs. Viral mRNAs are protected from such cleavage by a 5 0 -leader sequence. nsp15 cleaves the long viral sense-RNA in mature fragments, each with a 5 0 caplike structure made of a 2 0 -3 0 -cyclic phosphate, which structure protects the viral RNAs from host-mediated destruction. nsp10 stimulates two other mature viral proteins -nsp14 and nsp16. The N7-guanine methyltransferase activity of nsp14 adds the N7-methylguanosine cap to the viral mRNAs and recruits nsp16, which then adds a methyl group to the 2 0 -O-ribose of that N7-methylguanosine. These form a compact cap on each viral mRNA and prepare that for protein production using the host-cell machinery. All these, and some other proteins, help the RNA-dependent RNA-polymerase (RdRp), or nsp12, to efficiently replicate and transcribe the viral genome and to generate new infective virions (Fig. 1d) [3, 17, 33, 40, 44] .

SARS-CoV-2 do not lyse the host cell; instead, they 'bud'-off from the cell and infect nearby cells in the same way. As most of the human epithelial cells express ACE2, particularly the alveolar cells and those in the intestine, those infectious virions eventually spread throughout the body and may pose the host towards a critical condition [9] . But as no specific and confirmed drug or vaccination is available till date, immune-compromised people, for example persons having other diseases, may sometimes face severe complications due to COVID-19 and may even die due to acute respiratory distress syndrome (ARDS) [1, 3, 9, 18, 22, 33, 40, 42] . The complex signalling required for activating innate and adaptive immunity needs a lot of proteins to be expressed by the host. But in COVID-19, the initial stages of pathogenesis may suppress the immune responses of the host by suppressing the protein-production, as stated earlier [9, 18, 20, 40] .

Designing a successful and universal treatment regime for COVID-19 patients becomes critical due to these above discussed mechanism of infection of the virus and the respective host responses. Therefore, a combinatorial approach is needed to attack the disease from three sides: a drug to kill or stop the virus; a chemical blocker for any step of the establishment of the infection; and last but not the least, an immune-booster to support the actions of the former two. We have reviewed detailed information about COVID-19 and SARS-CoV-2 as published in literature and public databases, and analysed a few molecules for this above said treatment proposal.

Whole genome sequence of SARS-CoV-2 has been collected from National Center for Biotechnology Information (NCBI) (https://www.ncbi.nlm.nih.gov/nuccore/NC_ 045512). The '.pdb' files for the structures of viral proteins are downloaded from the Protein Data Bank (pdb) site (https://www.rcsb.org/). The characteristic of each of the proteins has been collected form NCBI, Swiss Model Repository, and pdb site.

Interactions of the viral proteins with the drug candidates [https://drugbank.ca] have been checked by the virtual screening tool PyRx and protein-ligand dockings have been checked by AutoDock Vina. These softwares have been downloaded as a package from http://autodock. scripps.edu/. The charts shown in Figs. 2 and 3 have been prepared with Microsft Excel. We have chosen the drugs which show at least one interaction with at least one viral protein with at least -0.7 kcal/mol of binding energy. 

After successful docking of some drug candidates, the interactions of the regions of viral proteins with the regions of the drug candidates have been checked by the PyMOL software downloaded from https://pymol.org/. Specific interactions with amino acids of viral proteins and atoms of the drugs have been analysed by the Discovery Studio Visualizer downloaded from the link https://www.3dsbio via.com/products/collaborative-science/biovia-discoverystudio/visualization-download.php.

Based on the experiences on SARSCoV, MERS-CoV, Ebola virus, malaria, and influenza, a few antiviral drugs are thought to effectively stop the SARS-CoV-2 spread [18, 28, 42] . Oseltamivir, Peramivir, Zanamivir, Ganciclovir, Acyclovir, and Methylprednisolone are already reported to be almost ineffective against SARS-CoV-2. Some other antiviral drugs like Umifenovir, Galidesivir, Ribavirin, Triazavirin, Ritonavir, Nitazoxanide, Favipiravir, Lopinavir, Ritonavir, Nafamostat, Darunavir and Remdesivir, and an antimalarial drug Chloroquine, have been used separately or in combination to treat COVID-19 patients. Though some effects and even recovery is reported for each of those treatment plans, none are found promising except a combination of Remdesivir and Chloroquine [18, 21, 31, 32, 38, 39, 42] . Viral infections can suppress host immunity, and previous reports show that application of immune-boosters like interferons along with an antiviral drug can help survival and prognosis [6, 31, 39] . Therefore scientists are working on combinatorial approaches using different drugs like Remdisivir and/ or Chloroquine along with immune-boosters. Recently, a Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral… blocker for ACE2 or TMPRSS2 is being tried to prevent the viral entry into the host cell. Interestingly, WHO has announced a combinatorial approach using Remdisivir, Chloroquine, a blocker as said above, and an immunebooster as said above [18, 20, 40, 42] . We have screened a lot of candidate molecules by checking the binding properties of those with different essential viral proteins separately. The possible efficacy of any candidate drug helped us suggest a possible combinatorial treatment plan to be implemented for trials.

Remdesivir, Galidesivir, and Pirodavir are the choice of antiviral drugs

After initial screening, we have finalized a set of six antiviral drug candidates for detailed study to propose the combinatorial therapy ( Remdesivir has already proved its efficacy against SARS-CoV-2. In our screening methods, we also have found that this drug can interact with a variety of viral proteins. Two other drugs, Galidesivir and Pirodavir, also seem promising as they can target more than one viral protein ( Fig. 2 ; Table 1, Supplementary Table 1) . Interestingly, none of these can interact effectively with the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein; thereby they cannot prevent the entry of the virus into the host cell ( Supplementary Figs. 1 and 2 ).

Some other drugs may serve as the promising candidates for using in combination with the antivirals A Chloroquine derivative, Hydroxychloroquine, is being widely used as a promising treatment strategy for COVID-19 [2, 7, 40] . Though we have found Chloroquine to interact with some SARS-CoV-2 proteins (Fig. 3a) , it should be noted that Hydroxychloroquine can reduce both innate and adaptive immune responses significantly by suppressing Toll-like receptor signalling (TLR) pathways [5, 34, 37] . Therefore the use of Chloroquine molecule in must be monitored carefully, and we exclude this known molecule from our proposals.

We have searched for a few FDA-(the U.S. Food and Drug Administration) approved drugs and/or chemical which might prove them promising for the management of COVID-19 (Table 1) [23]. A recent report has already suggested Ivermectin for treating COVID-19, though the results are not confirmed in humans [2, 12] . Looking on Chloroquine, we searched for other antimalarial drugs approved by FDA. We found that many of those show promising interactions with viral proteins (Fig. 3b) . Depending upon such possible interactions and reported side effects, we inferred that Proguanil, Artesunate, and Mefloquine may serve as candidates for the proposed combinatorial therapy. Artementher and Quinine may also be tested, but they show less favourable interactions (Fig. 3b-d; Table 1, Supplementary Fig. 2) . Though Amodiaquine belongs to the WHO safe drug list, we have excluded that for its rare but serious side effects and interactions with certain genotype [12] .

Host cell entry of SARS-CoV-2 should be prevented None of the above chosen antiviral and antiparasitic drugs can interact with the Spike-RBD and RdRp. Therefore, they cannot prevent the viral entry as well as its replication. We have concentrated our next choice on any blocker which can prevent viral entry (Supplementary Table 2 ) [19, 20] . Angiotensin-converting enzyme (ACE) cleaves angiotensin I to generate angiotensin II and this binds angiotensin II type 1 receptor (AGTR1) which constricts blood vessels, thereby elevates blood pressure. On the other hand, ACE-2 inactivates angiotensin II and helps vasodilation. Inhibitors to AGTR1, like Losartan and Olmesartan, are reported to increase ACE2 and thus vasodilation [15, 19] . Hypothetically, any blocker for ACE-2 might prevent host cell entry and thereby might prevent COVID-19 [11] . But the role of ACE-2 is essential for the survival of the host and it is already reported that reduced ACE-2 can lead to lung injury, arrhythmia and cardiac failure. In addition ACE-2 is found in a variety of organs and SARS-CoV-2 attacks those organs also resulting in low ACE-2 [20, 27, 35] . Therefore, the blockers against ACE or AGTR1 might be helpful as they can increase ACE-2 and might prevent pneumonia seen in COVID-19, as suggested by some [13, 43] .

A recent report also suggests for an inhibitor for TMPRSS2, camostat mesylate, to inhibit the priming of spike glycoprotein and subsequent entry into the host cell [20] . Previously another inhibitor for TMPRSS2, Nafamostat, has been suggested for treating MERS-CoV and Ebola infections [43] . It is to be noted that SARS-CoV-2 is much similar to MERS-CoV and therefore, Nafamostat may also serve as a potential candidate for preventing SARS-CoV-2 entry into the host-cells.

Host immunity plays the most important role for establishment and prognosis of any infection and supplements to Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral… boost immunity may be given to COVID-19 patients as suggested by some [16, 30] . A healthy lifestyle and food helps immune system the most. But majority of the patients are not much immunocompetent due to reasons like unhealthy lifestyle, ageing, and poor socio-economic conditions. Therefore some approved supplements may be added to their treatment plan to fight COVID-19 successfully. Based on cited literature, we have chosen a few such candidates which might help treatment (Supplementary  Table 3 ) [10, 14, 16, 30] . As discussed in other reports, along with these, interferon(s) may be given to the patients as a support to the drugs [6] . 

COVID-19 has made people reporting novel findings in various fields regularly. But the first and foremost task at present is to make people survive through this hell. As per the literature published till date, no one drug would serve the purpose of curing a significant number of patients. Rather, a combination of molecules, each targeting a specific step of infection, would be helpful for a full-proof treatment plan; and this has also been suggested by WHO recently [40] . Thus we propose a set of possible combinatorial treatment plans including an antiviral, an anitiparasitic drug, and an inhibitor for preventing host-cell entry. Additionally, we propose the use of some supplements and interferon(s) for boosting immunity and to support the effects of the drugs in immune-compromised patients. Of note, these supportive molecules and ACE-2 induction by the above said inhibitors may also help prevent cytokine storm [27, 35] . Though this study has been done in silico and needs wetlab validations, most of these molecules are FDA-approved and has gone through the clinical trials. Therefore practising our proposal would help reduce the time for deciding about the treatment plans to be adopted in specific groups of people. Though we have checked drug interactions from public databases, it should be noted that the dose and dosage should be finalized very carefully by efficient and experienced healthcare professionals to prevent any unwanted adverse result(s). We hope that this study would pave a new thought to help the decision makers for the proper and widespread management of COVID-19.

Acknowledgements Post-doctoral fellowship to the first author has been provided by Indian Council of Medical research, Government of India (Proposal ID. 2019-4919). A part of the work has been done using the High Performance Computing facilities provided by Indian Institute of Delhi. The corresponding author is a Fellow of the Indian Virological Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding No funding was available for the work.

Data availability Not required.

Conflicts of interest The authors declare that they have no conflict of interest.

Ethics approval Not applicable.

Code availability Not applicable. 

/01/30/limited-data-may-skew-assumptions-severity-cor onavirus-outbreak/ Accessed

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Treatment of SARS with human interferons

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Origin and evolution of pathogenic coronaviruses

The role of vitamin D in suppressing cytokine storm in COVID-19 patients and associated mortality

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Malaria distribution, prevalence, drug resistance, and control in Indonesia

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Can vitamin C prevent or treat COVID-19

Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by Olmesartan, an angiotensin II receptor blocker

A review on nature's immune boosters

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

The origin, transmission and clinical therapies on coronavirus disease 2019 [COVID-19] outbreak-an update on the status

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

First case of 2019 novel coronavirus in the United States

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China

Angiotensin-converting enzyme 2 protects from severe acute lung failure

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] infected pneumonia

The 15 best supplements to boost your immune system right now

Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of Lopinavir/Ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Good ACE, bad ACE do battle in lung injury, SARS

Structural basis of receptor recognition by SARS-CoV-2

Toll-like receptors

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus [2019-nCoV] in vitro

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV N

China: a modelling study

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay

A genomic perspective on the origin and emergence of SARS-CoV-2

Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak